Press release

Gossamer Bio to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 12, 2020

SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and

articleGossamer Bio, Inc.May 8, 20203/company/gossamer-bio-inc/news/gossamer-bio-to-announce-first-quarter-2020-financial-results-and-host-conference
Gossamer Bio to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 12, 2020

About this update from Gossamer Bio, Inc.

[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its first quarter 2020 financial results on Tuesday, May 12, 2020.\n\n\nIn connection with the earnings release, Gossamer’s management team will host a live conference call and webcast at 4:30 p.m. ET on Tuesday, May 12, 2020, to discuss the Company’s financial results and provide a corporate update.\n\n\nConference ID: 8593375\nDomestic Dial-in Number: (833) 646-0603\nInternational Dial-in Number: (929) 517-9782\nLive Webcast: https://edge.media-server.com/mmc/p/wf9kdou9\n\n\nA replay of the audio webcast will be available for 30 days on the Investors section of the Company's website, www.gossamerbio.com.\n\n\nAbout Gossamer Bio\n\n\nGossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20200508005062/en/\n\nFor Investors and Media:\nGossamer Bio Investor Relations\[email protected]\n\nSource: Gossamer Bio, Inc.","length":3028,"tagName":"div"}]

More updates from Gossamer Bio, Inc.